# Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

> **NCT01871571** · PHASE2 · UNKNOWN · sponsor: **University of Southern California** · enrollment: 17 (actual)

## Conditions studied

- Mucinous Adenocarcinoma of the Rectum
- Signet Ring Adenocarcinoma of the Rectum
- Stage IIA Rectal Cancer
- Stage IIB Rectal Cancer
- Stage IIC Rectal Cancer
- Stage IIIA Rectal Cancer
- Stage IIIB Rectal Cancer
- Stage IIIC Rectal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** oxaliplatin
- **DRUG:** leucovorin calcium
- **DRUG:** fluorouracil
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01871571
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-08-02
- **Primary completion:** 2022-06-24
- **Final completion:** 2023-06-24
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01871571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01871571, "Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01871571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*